R2 Technology banks $16 million in venture capital

AuntMinnie.com staff writers
Jan 1, 2001

R2 Technology, a Los Altos, CA-based computer-aided detection (CAD) software developer, announced raising $16 million in its most recent round of venture capital funding. The total financing to date obtained by the company is $60 million.

The company plans on using the investment capital to fund further development of its ImageChecker software. The product, which performs more than 9 billion calculations on a mammography film to identify suspicious lesions indicative of breast cancer, is the first FDA-approved CAD system on the market

By AuntMinnie.com staff writers
January 2, 2001

Related Reading

Kodak takes equity stake in R2, November 24, 2000

iMammogram.com launches CAD service, September 20, 2000

R2 names Klein as CEO, May 19, 2000

R2 Technology highlights journal study, May 3, 2000

R2 gets approval to market ImageChecker in Japan, February 7, 2000

Copyright © 2001 AuntMinnie.com

Latest in Breast
Bac
CureMetrix secures FDA clearance for cmAngio 2.0
August 17, 2026
Breast Dbt 400
Longitudinal DBT could help improve long-term cancer risk prediction
August 13, 2026
Breast Mammo Computer 400 (3)
AI tools may not meet breast radiologists' expectations in practice
August 12, 2026
Mri Breast 400
NME breast lesions have high malignancy rate on MRI-guided biopsy
August 10, 2026
Related Stories
187x200 Am Logo
Companies
AuntMinnie.com
Tact2
Breast
TACT technique offers 3-D mammograms
Augment1
Breast
MLO view
Gammasmall07 19 00 rn
Nuclear Medicine
Gamma Medica sees better lymph node imaging with handheld probe
More in Breast
CureMetrix secures FDA clearance for cmAngio 2.0
By AuntMinnie.com staff writers
The update introduces BAC quantification, age-based BAC percentile scoring compared against a reference library of more than 170,000 studies.
August 17, 2026
Bac
Longitudinal DBT could help improve long-term cancer risk prediction
By Amerigo Allegretto
A longitudinal DBT model outperformed other models based on mammography and clinical factors in predicting five-year cancer risk.
August 13, 2026
Breast Dbt 400
AI tools may not meet breast radiologists' expectations in practice
By Amerigo Allegretto
AI tools in breast imaging may have more modest clinical impact on recall and biopsy rates.
August 12, 2026
Breast Mammo Computer 400 (3)
NME breast lesions have high malignancy rate on MRI-guided biopsy
By Amerigo Allegretto
Biopsies from women with a known ipsilateral malignancy have a higher frequency of breast cancer.
August 10, 2026
Mri Breast 400
DBT-based foundational model classifies breast density
By Amerigo Allegretto
DBT-DINO showed strong performance in classifying breast density from DBT images.
August 4, 2026
(A) Free-response receiver operating characteristic (FROC) curve for DBT-DINO and DINOv2 (Meta AI) on the detection task. DINOv2 achieved higher sensitivity than DBT-DINO across most false-positive thresholds. (B) Detection rates of DBT-DINO and DINOv2 for lesions that were ultimately found to be benign (n = 70) and lesions that were found to be cancerous (n = 66). Error bars represent 95% CIs estimated via patient-level bootstrapping with 1000 repetitions. Both models showed similar detection rates for cancerous lesions, whereas DINOv2 detected more benign lesions than DBT-DINO. (C) Example bounding box predictions for DBT-DINO and DINOv2 on the detection test set. Each image is a single two-dimensional section from a three-dimensional digital breast tomosynthesis volume; the first column shows a mediolateral oblique view, and the second and third columns show craniocaudal views. Both models struggled to detect very small lesions, such as the 3-mm-diameter lesion shown in the first column. FP = false positive.
RadSite publishes clinical coverage guideline for breast CBCT imaging
By AuntMinnie.com staff writers
The guide outlines how breast CBCT should be used when conventional imaging approaches are inconclusive or inaccessible.
July 30, 2026
Rad Site
CEM finds breast cancer at baseline, incidence screening
By Amerigo Allegretto
Incidence screening with CEM maintains high performance and may offer more benefits over baseline CEM screening.
July 28, 2026
Images in a 70-year-old asymptomatic woman with a prior excisional biopsy in the left breast yielding lobular carcinoma in situ 3 years earlier. Screening contrast-enhanced mammography (CEM) was performed, which was considered a prevalence screen as the woman had no prior breast MRI in the past 3 years and no prior CEM. (A) Low-energy (26–30 kVp) mediolateral oblique (MLO) and (B) craniocaudal (CC) views show surgical clips but no abnormality. (C) Recombined MLO and (D) CC images show an enhancing mass in the medial left breast (arrows). Biopsy revealed invasive lobular carcinoma. Size was 0.2 cm; tumor grade II/III; negative lymph nodes; and estrogen receptor–positive, progesterone receptor–positive, and human epidermal growth factor receptor 2–negative.
Women's Imaging MinnieCast, Episode 13: Partial breast irradiation in the spotlight
By Amerigo Allegretto
Two committee members for ASTRO's PBI guidelines share insights about this breast cancer treatment option.
July 17, 2026
Minnie Cast Thumbnail (15)
Incorrect AI suggestions influence reader performance on mammography
By Amerigo Allegretto
The biggest impact on reader performance stemmed from false-negative AI suggestions.
July 14, 2026
A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.
Breast cancer screening higher among civically engaged women
By Amerigo Allegretto
Women who voted, attended a public meeting, or volunteered are more likely to get their breast cancer screening.
July 14, 2026
Mammogram Calendar 400
CEM on par with MRI for breast cancer diagnosis, local staging
By Amerigo Allegretto
CEM alone in a prospective study achieved perfect sensitivity and negative predictive value in diagnosing breast cancer.
July 10, 2026
MRI false positive for additional disease, (top to bottom): A. Index lesion—grade 2 invasive ductal carcinoma; B. MRI lesion two, upper inner quadrant: Stromal sclerosis and columnar cell change; C. MRI lesion three, upper outer quadrant: No ultrasound correlate, no malignancy on follow-up; D. CEM marked background parenchymal enhancement with a unifocal retroareolar lesion demonstrating wash-out on delayed MLO. Images are republished under a Creative Commons license (CC BY 4.0).
Siemens Healthineers gets FDA nod for CEM on Mammomat B.brilliant
By AuntMinnie.com staff writers
Siemens Healthineers has received FDA clearance for CEM and CEM biopsy capabilities for its Mammomat B.brilliant system.
June 30, 2026
Mammomat B.brilliant breast imaging system
Page 1 of 584
Next Page